comparemela.com

Latest Breaking News On - Med fine capital - Page 2 : comparemela.com

Degron Therapeutics Raises $22M in Series A Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

San diegoUnited statesJing yuLily zouYong cangShanghaitech universityDegron therapeuticsMed fine capitalDyee capitalBaidu ventureNeux capitalYuanbio venture

Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform

/PRNewswire/ Degron Therapeutics ("Degron"), a biotechnology company developing a new class of small-molecule medicines that target previously undruggable.

Jing yuLily zouYong cangShanghaitech universityDyee capitalBaidu ventureNeux capitalYuanbio ventureDegron therapeuticsMed fine capital

Degron Raises $22 Million to Advance Molecular-Glue-Based Protein Degradation Platform

Degron Raises $22 Million to Advance Molecular-Glue-Based Protein Degradation Platform
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesJing yuLily zouYong cangShanghaitech universityFine capitalDyee capitalBaidu ventureNeux capitalYuanbio ventureDegron therapeuticsMed fine capital

Next-generation Precision Medicine Company Allorion Therapeutics Completes Series A Financing Round

/PRNewswire/ Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, today announced the.

United statesHong kongChen kanShenzhen stock exchangeShanghai stock exchangeQiming venture partnersOctagon capitalFirstred capitalMed fine capitalAllorion therapeuticsSan francisco bayCurrently qiming venture partnersGretai securities market

Next-generation Precision Medicine Company Allorion Therapeutics Completes Series A Financing Round

Focusing on small molecule drug discovery and development for cancer and autoimmune diseases BOSTON, Nov. 24, 2021 /PRNewswire/ Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, today announced the completion of $40M Series A financing. This financing round is led by Qiming Venture Partners and participated by IDG Capital, Octagon Capital, Firstred.

United statesHong kongChen kanShenzhen stock exchangeShanghai stock exchangeQiming venture partnersOctagon capitalFirstred capitalMed fine capitalAllorion therapeuticsSan francisco bayCurrently qiming venture partnersGretai securities market

vimarsana © 2020. All Rights Reserved.